4D Molecular Therapeutics (FDMT) director reports 9,333-share option exercise

Rhea-AI Filing Summary

4D Molecular Therapeutics director Charles Theuer reported exercising a stock option for 9,333 shares of common stock at $1.14 per share on December 12, 2025. The transaction is shown as an acquisition of common stock following the exercise of a fully vested stock option originally granting the right to buy 9,333 shares at $1.14, with an expiration date of March 9, 2026. After this transaction, Theuer directly beneficially owned 41,684 shares of 4D Molecular Therapeutics common stock and held no remaining derivative securities from this option grant.

Insider Trade Summary

9,333 shares exercised/converted

Mixed 2 txns

Insider THEUER CHARLES

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	9,333	$0.00	--
Exercise	Common Stock	9,333	$1.14	$11K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 41,684 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

THEUER CHARLES

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		M		9,333	A	$1.14	41,684	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.14	12/12/2025		M			9,333	(1)	03/09/2026	Common Stock	9,333	$0	0	D

Explanation of Responses:

1. Fully vested.

	/s/ Scott Bizily as Attorney-in-Fact for Charles Theuer	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did FDMT director Charles Theuer report?

Charles Theuer, a director of 4D Molecular Therapeutics, reported exercising a stock option and acquiring 9,333 shares of common stock at $1.14 per share.

When did the reported FDMT stock transaction take place?

The earliest transaction date disclosed for the 4D Molecular Therapeutics (FDMT) filing is December 12, 2025.

How many 4D Molecular Therapeutics (FDMT) shares does Charles Theuer own after the transaction?

Following the reported transaction, Charles Theuer directly beneficially owned 41,684 shares of 4D Molecular Therapeutics common stock.

What derivative security was involved in the FDMT Form 4 filing?

The derivative security was a stock option (right to buy) with an exercise price of $1.14 per share for 9,333 underlying common shares.

What happened to the stock option position after the FDMT transaction?

After the option exercise, the number of derivative securities beneficially owned was reported as 0, indicating the 9,333-share option position was fully exercised or disposed of.

What was the vesting status and expiration date of the exercised FDMT stock option?

The filing notes the option as fully vested, with an expiration date of March 9, 2026 for the stock option covering 9,333 shares.